Medscape October 10, 2024
In January, after the DermaSensor became the first artificial intelligence (AI)-enabled device cleared by the US Food and Drug Administration (FDA) to evaluate lesions suggestive of skin cancer, the potential of the device to bridge a gap in access to dermatologists drew significant attention.
In a letter published in npj Digital Medicine, for example, Stephen Gilbert of the Else Kröner Fresenius Center for Digital Health at Dresden University of Technology, Dresden, Germany, and coauthors from Harvard University, Boston, postulated that the use of the DermaSensor, a handheld device that uses elastic scattering spectroscopy (ESS) to identify skin lesions concerning skin cancer, “could strengthen the diagnostic abilities of PCPs [primary care physicians] who normally refer such cases, and could therefore meaningfully...
Today's Sponsors
Today's Sponsor